دورية أكاديمية
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis
| العنوان: | Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis |
|---|---|
| المؤلفون: | Boutros, Andrea, Tanda, Enrica Teresa, Croce, Elena, Catalano, Fabio, Ceppi, Marcello, Bruzzone, Marco, Cecchi, Federica, Arecco, Luca, Fraguglia, Matteo, Pronzato, Paolo, Genova, Carlo, Del Mastro, Lucia, Lambertini, Matteo, Spagnolo, Francesco |
| المساهمون: | Boutros, Andrea, Tanda, Enrica Teresa, Croce, Elena, Catalano, Fabio, Ceppi, Marcello, Bruzzone, Marco, Cecchi, Federica, Arecco, Luca, Fraguglia, Matteo, Pronzato, Paolo, Genova, Carlo, Del Mastro, Lucia, Lambertini, Matteo, Spagnolo, Francesco |
| بيانات النشر: | ELSEVIER SCI LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND |
| سنة النشر: | 2023 |
| المجموعة: | Università degli Studi di Genova: CINECA IRIS |
| مصطلحات موضوعية: | Advanced, BRAF, CTLA-4, Immunotherapy, Ipilimumab, LAG-3, Melanoma, Nivolumab, PD-1, Relatlimab |
| الوصف: | Background: Treatment options for advanced melanoma have increased with the US Food and Drug Administration approval of the anti-LAG3 plus anti-PD-1 relatlimab/ nivolumab combination. To date, ipilimumab/nivolumab is the benchmark of overall survival, despite a high toxicity profile. Furthermore, in BRAF-mutant patients, BRAF/MEK in-hibitors and the atezolizumab/vemurafenib/cobimetinib triplet are also available treatments, making the first-line therapy selection more complex. To address this issue, we conducted a systematic review and network meta-analysis of the available first-line treatment options in advanced melanoma. Methods: Randomised clinical trials of previously untreated, advanced melanoma were in-cluded if at least one intervention arm contained a BRAF/MEK or an immune-checkpoint inhibitor (ICI). The aim was to indirectly compare the ICIs combinations ipilimumab/nivo-lumab and relatlimab/nivolumab, and these combinations with all the other first-line treat-ment options for advanced melanoma (irrespective of BRAF status) in terms of activity and safety. The coprimary end-points were progression-free survival (PFS), overall response rate (ORR) and grade >= 3 treatment-related adverse events (>= G3 TRAEs) rate, defined according to Common Terminology Criteria for Adverse Events. Results: A total of 9070 metastatic melanoma patients treated in 18 randomised clinical trials were included in the network meta-analysis. No difference in PFS and ORR was observed between ipilimumab/nivolumab and relatlimab/nivolumab (HR = 0.99 [95% CI 0.75-1.31] and RR = 0.99 [95% CI 0.78-1.27], respectively). The PD-(L)1/BRAF/MEK inhibitors triplet combinations were superior to ipilimumab/nivolumab in terms of both PFS (HR = 0.56 [95% CI 0.37-0.84]) and ORR (RR = 3.07 [95% CI 1.61-5.85]). Ipilimumab/nivolumab showed the highest risk of developing >= G3 TRAEs. Relatlimab/nivolumab trended to a lower risk of >= G3 TRAEs (RR = 0.71 [95% CI 0.30-1.67]) versus ipilimumab/nivolumab. Conclusion: Relatlimab/nivolumab ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/37196485; info:eu-repo/semantics/altIdentifier/wos/WOS:001002463900001; volume:188; firstpage:64; lastpage:79; numberofpages:16; journal:EUROPEAN JOURNAL OF CANCER; https://hdl.handle.net/11567/1147655Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85159221302 |
| DOI: | 10.1016/j.ejca.2023.04.010 |
| الإتاحة: | https://doi.org/10.1016/j.ejca.2023.04.010Test https://hdl.handle.net/11567/1147655Test |
| رقم الانضمام: | edsbas.5EF34925 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ejca.2023.04.010 |
|---|